MedQIA has developed a software toolkit of image analysis routines that forms the basis of an Imaging Biomarker Information System (IBIS). It employs a model-based engine to segment the lung, lobes, segments, and airways. IBIS provides computer-assisted diagnosis of the lung from CT for early diagnosis, treatment planning and outcome assessment.
MedQIA applies cutting-edge biomarkers based on lung texture analysis; these include assessment of honeycombing, ground-glass and lung fibrosis scoring, applied in assessment of scleroderma lung disease and interstitial pulmonary fibrosis (IPF).
The QIA approach complements conventional pulmonary function tests (PFTs) because it is minimally-invasive and able to perform both global and regional assessment of the lung, thus providing greater sensitivity. IBIS allows a variety of validated quantitative measures to be derived from any segmented lung region or subregion (e.g. lung lobe, segment, anterior, middle or posterior zone, central or peripheral zone and combination zones such as posterior peripheral, middle peripheral, etc.).
Lung imaging biomarkers include: Volumetry, Attenuation Analysis, Texture Classification, Fibrosis Scoring, Dynamic Imaging, Airway Morphometry, and Fissure Integrity Scoring.
Anti-inflammatory cytokine linked to capillary obstruction and cognitive decline in diabetes